It is worth noting that oxaliplatin, cetuximab, and 5-FU combined with C6-ceramide increase the inhibition rate in both two CRC cell lines, and the inhibitory effect on KRAS mutant cells is particularly significant [51]. This evidence concerns the gene KRAS and colorectal carcinoma.